List prices for brand-name drugs have de­clined sig­nif­i­cant­ly in 2026. But the rea­sons be­hind it may have more to do with a Biden-era law than...

Tavneos’ with­draw­al from the Eu­ro­pean mar­ket is cre­at­ing chal­lenges for CSL Vi­for.

CSL Lim­it­ed, Vi­for’s Aus­tralian par­ent com­pa­ny, said Vi­for’s rev­enue is ex­pect­edto fall...

A pa­tient with an au­toim­mune dis­ease has died af­ter re­ceiv­ing an ex­per­i­men­tal ge­net­ic med­i­cine from a biotech start­up in Chi­na, End­points News has learned.

The...

A week af­ter end­ing de­vel­op­mentof a rare dis­ease drug from a $270 mil­lion ac­qui­si­tion, Bio­Marin is back at the deal­mak­ing ta­ble for a very...

Af­ter a tur­bu­lent few years re­search­ing ALS, Amy­lyx Phar­ma­ceu­ti­cals said it has notched a suc­cess in its at­tempt to re­build as a GLP-1 biotech.

A...

Leo Phar­ma said it will pay Japan’s Tan­abe Phar­ma up to $435 mil­lion in up­front and near-term pay­ments to li­cense an oral drug for a...